Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directors

SAN DIEGO--(BUSINESS WIRE)-- Endeavor BioMedicines, a clinical-stage company developing therapies for fibrotic disease and oncology, announced that the company has appointed Enoch Kariuki, Pharm.D. to the Endeavor BioMedicines Board of Directors. Dr. Kariuki is an established life sciences executive with extensive strategic, operational, and financial experience.

“Dr. Kariuki is an excellent addition to our esteemed board of directors, who are helping us advance our pipeline of therapies for patients with fibrosis and cancer,” said John Hood, Ph.D., co-founder, CEO and chairman, Endeavor BioMedicines. “His executive leadership experience, together with his corporate development and operating expertise, are invaluable as we continue to build the company and advance our clinical programs for ENV-101 for the treatment of fibrotic lung diseases and ENV-501 for the treatment of HER3 expressing tumors. I look forward to having him on the team.”

Dr. Kariuki has more than fifteen years of experience in healthcare strategy, life sciences investment banking, venture capital and business development. Most recently, he served as chief executive officer of Lengo Therapeutics (acquired by Blueprint Medicines). Previously, Dr. Kariuki served as the chief financial officer of VelosBio (acquired by Merck), where he led all finance-related and investor relations functions. Prior to VelosBio, he served as senior vice president, Corporate Development, at Synthorx, where he led the company’s IPO, managed relationships with bankers, sell-side equity analysts and investors, and headed the business development process that concluded with the sale of Synthorx to Sanofi. Before Synthorx, Dr. Kariuki was vice president at H.I.G. Capital, a $50 billion+ private equity firm, where he invested in and served on the boards of multiple life sciences companies.

“Endeavor BioMedicines’ pipeline of differentiated therapeutic options has the potential to make a significant difference in the treatment of fibrotic lung diseases as well as cancer,” said Dr. Kariuki. “This, coupled with a talented and focused management team equipped to execute on its development strategy, makes this an incredibly promising and compelling company. I look forward to working closely with the other members of the Board and management team to bring important new treatment options to patients in need.”

About Endeavor BioMedicines

Endeavor BioMedicines, Inc., is a clinical-stage company developing novel therapies for fibrosis and oncology. The Company combines best-in-class therapeutics with an evolved understanding of terminal diseases to develop medicines with the potential to reverse severe health conditions. Endeavor BioMedicines’ lead program, ENV-101, is a Hedgehog signaling inhibitor currently in Phase 2 studies treating idiopathic pulmonary fibrosis (IPF). The second program is a HER3-targeted antibody drug conjugate (ADC) that will begin clinical development in 2024 for the treatment of multiple solid tumors. Endeavor BioMedicines has an innovative and focused team that works to develop therapeutics that help patients feel better and live longer. For additional information, visit www.endeavorbiomedicines.com or connect on LinkedIn and X (formerly Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20231219224558/en/